Early-Onset Schizophrenia Study*
βFor each GRIN2Anull-related mental disorder, we systematically compared cumulative disease incidence of GRIN2Anull carriers versus the average population using FinRegistry data as a nationwide control cohort, containing longitudinal electronic health records for the whole Finnish population (>5 million individuals, spanning 21 years of individual-level data).β
βOur findings establish GRIN2Anull as the first monogenetic predisposition to a broad spectrum of early-onset mental disorders, including early-onset schizophrenia.β
βWe restricted the analysis to age bins in which the hazard is proportional as required by the Cox-PH model. GRIN2Anull carriers showed elevated lifetime incidence of psychotic disorders
(Hazard Ratio = 87,
95% Confidence Interval = [26.7-283.4],
p-value = 1.3e-13,
n = 4,
age bins = 0-12).β
βStrikingly, all four individuals in our cohort of GRIN2Anull-related mental disorders who received L-serine experienced phenotypic improvements, such as ceasing of hallucinations, remission of paranoid symptoms or improvement of behavioral disorder.β
*Note: This study is particularly interesting to me personally as a parent of a child, now an adult, who began experiencing hallucinations at four years of age. Look at that hazard ratio! Yes it is a tiny sample, but that is what one gets with early-onset psychosis which is extremely rare.
#Schizophrenia #Genetics #Psychiatry #Neuroscience #Medicine #Statistics
https://www.nature.com/articles/s41380-025-03279-4.pdf